Abstract: There is provided a biliary atresia diagnosis support management system including a server, the server including a transmission/reception unit receiving an image of stool from a living body and a determination unit determining whether biliary atresia is contracted or not from the image, wherein the server further includes: a management unit including a usage fee saving unit saving received usage fees and a donation sending unit for sending a donation from the saved usage fees; and a doctor's determination request processing unit requesting a determination by a doctor if the determination unit determines that there is a suspected positive result; and if it is diagnosed that the living body needs treatment for biliary atresia as a result of a thorough examination, the server pays a donation for the treatment from the usage fees saved in the usage fee saving unit via the donation sending unit.

Abstract: A reagent for detecting gene product, the reagent comprising a probe or chemical modulation that specifically binds to an alternative splicing junction of a gene product of human PTCH1 gene, the expression of the gene product from gene products of the human PTCH1 gene being varied due to the unusual alternative splicing, for use for measuring the abundance of the gene product contained in a human sample.

Abstract: A reagent for detecting gene product, the reagent comprising a probe or chemical modulation that specifically binds to an alternative splicing junction of a gene product of human PTCH1 gene, the expression of the gene product from gene products of the human PTCH1 gene being varied due to the unusual alternative splicing, for use for measuring the abundance of the gene product contained in a human sample.

Abstract: It is intended to provide a method of assessing cancerous conditions, which is useful in diagnosing cancer in a therapy or a preventive therapy for cancer diseases or a maintenance therapy therefor, and a reagent for detecting a gene product to be used in the above method. The cancerous conditions of a human-origin specimen is assessed by using, as an indication, the content of a gene product, which shows an increase or a decrease in the expression thereof due to an unusual alternative splicing, from gene products obtained from human PTCH1 gene contained in the human-origin specimen.